Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of meetings, deadlines, Skype calls, conferences, and what-not has, of course, returned. No surprise, though, because the world keeps spinning no matter how much we try to hit the brake pedal. So to cope, please join us for a delightful cup of stimulation. Our choice today is peppermint mocha, for those keeping track. Meanwhile, here are some tidbits. Hope you have a smashing day and do keep in touch. …

The Food and Drug Administration declined to approve a drug developed by Sanofi (SNY) and Lexicon Pharmaceuticals (LXRX)  intended for use with insulin in patients with Type 1 diabetes, Reuters writes. The decision comes about two months after an FDA advisory panel failed to reach a consensus over whether the once-daily oral drug, sotagliflozin, should be approved as an add-on to insulin therapy. The setback comes as Sanofi works to revive declining sales from its diabetes division and faces increasing pressure from politicians and patient groups over the rising cost of its insulin products.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy